Rankings
▼
Calendar
RIGL Q4 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$517M
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$15M
-59.3% YoY
Gross Profit
$15M
98.8% margin
Operating Income
-$17M
-112.6% margin
Net Income
-$17M
-111.7% margin
EPS (Diluted)
$-1.03
QoQ Revenue Growth
-26.2%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$148M
Total Liabilities
$94M
Stockholders' Equity
$54M
Cash & Equivalents
$23M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$15M
$38M
-59.3%
Gross Profit
$15M
$38M
-59.6%
Operating Income
-$17M
$3M
-784.7%
Net Income
-$17M
$3M
-632.8%
Revenue Segments
Gross Product
$16M
65%
Product
$14M
55%
Contract Revenues From Collaborations
$2M
6%
Research And Development Services And Others
-$376,000
-1%
Discounts And Allowances
-$3M
-10%
License
-$4M
-14%
← FY 2019
All Quarters
Q1 2020 →